[go: up one dir, main page]

GR1002616B - Synthesis and method of synthesis of a molecular (AE 37) of anticonvulsant, antidepressant and neuroleptic tropic action. - Google Patents

Synthesis and method of synthesis of a molecular (AE 37) of anticonvulsant, antidepressant and neuroleptic tropic action.

Info

Publication number
GR1002616B
GR1002616B GR960100061A GR960100061A GR1002616B GR 1002616 B GR1002616 B GR 1002616B GR 960100061 A GR960100061 A GR 960100061A GR 960100061 A GR960100061 A GR 960100061A GR 1002616 B GR1002616 B GR 1002616B
Authority
GR
Greece
Prior art keywords
synthesis
anticonvulsant
antidepressant
neuroleptic
molecular
Prior art date
Application number
GR960100061A
Other languages
Greek (el)
Inventor
-
Original Assignee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by filed Critical
Publication of GR1002616B publication Critical patent/GR1002616B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Synthesis of the molecule: tetrahydro - N,N -dimethyl - 2,2 - diphenyl -3- fouronomthamine (AE 37) which exhibits an anticonvulsant, antidepressant and neuroleptic action.
GR960100061A 1996-02-21 1996-02-21 Synthesis and method of synthesis of a molecular (AE 37) of anticonvulsant, antidepressant and neuroleptic tropic action. GR1002616B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR96100061 1996-02-21

Publications (1)

Publication Number Publication Date
GR1002616B true GR1002616B (en) 1997-02-20

Family

ID=10942335

Family Applications (1)

Application Number Title Priority Date Filing Date
GR960100061A GR1002616B (en) 1996-02-21 1996-02-21 Synthesis and method of synthesis of a molecular (AE 37) of anticonvulsant, antidepressant and neuroleptic tropic action.

Country Status (3)

Country Link
AU (1) AU1614097A (en)
GR (1) GR1002616B (en)
WO (1) WO1997030983A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11617734B2 (en) 2015-07-22 2023-04-04 Anavex Life Sciences Corp. Enantiomers of A2-73, analogues, and sigma agonist activity

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1003205B (en) * 1998-11-16 1999-09-03 Pharmaceutical use of two isomerous derivatives of tetrahydrofuranics:tetrahudro-n,n-dimethyl-5,5-diphenyl-3-furanomethanamine (ae14) and tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanomethanamine (ae37)
GR990100386A (en) * 1999-11-05 2001-07-31 A OR B (MONO- OR DI-ALKYLAMINOMETHYL)-C-BUTYROLACTONES AND THEIR CORRESPONDING TETRAHYDROFURAN ANALOGUES AS NEW PROTOTYPE NOOTROPES, ANTI-ANOIC (ALZHEIMER'S DISEASE), ANTIPELIPUS AND NEUROPROTECTIVE DRUGS WITH A UNIQUE MEDICATION OF ... .
GR1004208B (en) * 2001-10-15 2003-04-04 Αλεξανδρος Βαμβακιδης Aminotetrahydrofuran derivatives, muscarinic/sigma/sodium channel ligands, with synergic sigma/muscarinic (neuroactivating) and sigma/sodium channel (neuroprotective) components, as prototypical activating - neuroprotectors and neuroregenerative drugs
FR2897535B1 (en) * 2006-02-21 2012-07-20 Alexandre Vamvakides SIGMA LIGANDS: (MONO- OR DI-ALKYLAMINOALKYL) -Y-BUTYROLACTONES, THEIR AMINOTETRODRAFURAN ANALOGUES AND (1-ADAMANTYL) BENZENE (S) ALKYLAMINES AS PROTOTYPIC CELLULAR RECEPTOR MODULATORS
GR1005865B (en) * 2007-01-17 2008-04-07 Anavex Life Sciences Corp. NEW SIGMA LIGANDS with anti-apoptotic and/or pro-apoptotic action on the cells biochemical mechanisms and neuroprotective, anti-cancer, anti-metastatic, and anti-chronic inflammatory properties.
GR1006794B (en) 2009-02-26 2010-06-04 Αλεξανδρος Βαμβακιδης The new sigma(σ)-receptor ligands with anti-apoptotic and/or pro-apoptotic properties over cellular biochemical mechanisms, with neuroprotective, anti-cancer, anti-metastatic and anti-(chronic) inflammatory action.
GR1007322B (en) * 2010-03-09 2011-06-22 Βαμβακιδης, Αλεξανδρος Δημητριου Synthesis of 1-methyl-4-[4,4-diphenyl-4-(1-adamantyl)-butyl] piperazine and analogues thereof with anti-cancer properties
GR1007686B (en) * 2011-07-08 2012-09-12 Αλεξανδρος Δημητριου Βαμβακιδης Synthesis of (+)- and (-)-1-(5,5-diphenyltetrahydrofuran-3-yl)-n,n-dimethylmethylamine, (+)-and (-)-1-(2,2-diphenyltetrahydrofuran-3-yl)-n,n-dimethylmethylamine and (+)- and (-)-1-(2,2-diphenyltetrahydrofuran-3-yl)-n-methylmethylamine
JP2017531043A (en) * 2014-10-20 2017-10-19 アナベックス ライフ サイエンシズ コーポレイション A19-144, A2-73 and certain anticholinesterase inhibitors, compositions and methods for anti-seizure treatment
JP7304043B2 (en) * 2015-07-22 2023-07-06 アナベックス ライフ サイエンシズ コーポレイション Crystalline forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, methods of making such forms and pharmaceutical compositions thereof
US10507196B2 (en) 2016-01-26 2019-12-17 Anavex Life Sciences Corp. Neurodevelopmental disorder therapy
US10426754B2 (en) 2017-06-14 2019-10-01 Anavex Life Sciences Corp. Crystalline form of ANAVEX2-73 for the treatment of Alzheimer's disease
JP2020523417A (en) * 2017-06-14 2020-08-06 アナベックス ライフ サイエンス コーポレイション ANAVEX2-73 for the treatment of Alzheimer's disease
US11498908B2 (en) * 2018-04-12 2022-11-15 Anavex Life Sciences Corp. A2-73 crystalline polymorph compositions of matter and methods of use thereof
US20220249427A1 (en) * 2019-07-22 2022-08-11 Anavex Life Sciences Corp. Anavex2-73 for the treatment of genetic neurodevelopmental disorders
WO2021158586A1 (en) 2020-02-04 2021-08-12 Teva Pharmaceuticals International Gmbh Solid state forms of blarcamesine salts
US12018005B1 (en) 2023-07-25 2024-06-25 Egis Gyógyszergyár Zrt. Blarcamesine co-crystals for the manufacture of pharmaceutical dosage form
WO2025215672A1 (en) * 2024-04-12 2025-10-16 Dr. Reddy’S Laboratories Limited "process for preparation of blarcamesine"

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3532722A (en) * 1968-03-15 1970-10-06 Bristol Myers Co Spiro(dibenzo(a,d) (1,4) cycloheptadiene-5-4' - tetrahydrofurfurylamine) and mono- and dialkylated derivatives and their salts

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3532722A (en) * 1968-03-15 1970-10-06 Bristol Myers Co Spiro(dibenzo(a,d) (1,4) cycloheptadiene-5-4' - tetrahydrofurfurylamine) and mono- and dialkylated derivatives and their salts

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANN. PHARM. FR., vol. 43, no. 3, 1985, pages 257 - 264 *
CHEMICAL ABSTRACTS, vol. 104, no. 5, 3 February 1986, Columbus, Ohio, US; abstract no. 28402x, N. KOLOKOURIS ET AL.: "New amino ethers and amino lactones. Synthesis and pharmacological approach" page 17; column 1; XP002016943 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11617734B2 (en) 2015-07-22 2023-04-04 Anavex Life Sciences Corp. Enantiomers of A2-73, analogues, and sigma agonist activity

Also Published As

Publication number Publication date
AU1614097A (en) 1997-09-10
WO1997030983A1 (en) 1997-08-28

Similar Documents

Publication Publication Date Title
GR1002616B (en) Synthesis and method of synthesis of a molecular (AE 37) of anticonvulsant, antidepressant and neuroleptic tropic action.
AP9701018A0 (en) Squalene synthetase inhibitor compounds.
DE69730202D1 (en) AZID-FREE, GAS GENERATING COMPOSITIONS
ID18189A (en) 6.6-HETERO-BISICLIC SUBSTITUTED DERVATES
ZA977297B (en) Polymeric rheology modifiers.
ZA987750B (en) Rheology modification of polymers.
ID18249A (en) SUBSTITUTE 6.5-HETERO-BISICLIC SUBSTITUTED
ZA9710209B (en) Disinfecting microemulsions.
ZA973395B (en) Cylindrical electrolyzer assembly.
ZA977672B (en) Polyacrylamide polymerisation.
ZA978740B (en) Foliar fertilisers.
WO1996039512A3 (en) A cell line for the rapid expression of functional calcium channels
PL324221A1 (en) Novel beta-xylosidase, nucleotidic sequence encoding it and application thereof
DE69702544D1 (en) D, L-tartaric acid containing gas generating compositions
ZA98387B (en) Novel microorganisms.
AU6180896A (en) Improved synthesis of 2,4,6,8,10,12-hexabenzyl-2,4,6,8,10,12-hexaazatetracyclo{5.5 .0.05,9.03,11}dodecane
ZA974084B (en) Novel α-glucuronidases, production hereof and their uses.
ZA979670B (en) Piperazino derivatives as neurokinin antagonists.
IL139604A0 (en) Novel peptides
ID19571A (en) RAW 1.4-BUTANADIOL PURIFICATION PROCESS
EP0878464A4 (en) Process for producing alpha.beta-unsaturated nitrile
EP0731160A3 (en) Perfume containing (6E)-2,3-dihydrofarnesol
BG103650A (en) Method for the preparation of eprosartan
ZA966533B (en) Impact-type anchor.
DE69817993D1 (en) Fuel compositions containing polyamines, aromatic polyalkyl esters

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees

Effective date: 20130904